reports
- Oscar Haffen Lamm
Cinclus: reaches agreement with the EMA on the PIP
Cinclus Pharma has secured an agreement with the EMA Paediatric Committee (PDCO) on their Paediatric Investigation Plan (PIP) for linaprazan glurate, a necessary step toward obtaining marketing approval for adult use in the EU. A PIP outlines the approach for studying new medications in paediatric
- Oscar Haffen Lamm
Cinclus: Q2 reiterated phase 3 trial timeline
Cinclus Pharma reported its Q2'24 results with a cash position at SEK 684.72m and an EBIT at SEK (37.329m). On the operations side, it has been reiterated that i) the company is looking to enroll the first patient in the 1st phase 3 study in 2025, with a readout expected in 2026, and ii) its Chines
- Oscar Haffen Lamm
Cinclus: Positive read-x, US market showing growing interest in PCABs
Phathom Pharma reported its Q2 report yesterday, which highlighted a positive launch of its 1st generation PCAB Voquezna (vonoprazan), where filled prescriptions amounted 35,000 (+265% QoQ) for the quarter, with 77% of total US commercial lives covered. We are encouraged by such a positive launch t
- Oscar Haffen Lamm
Better, faster, stronger! Taking on the eGERD market
Cinclus Pharma is a Swedish late-stage biopharmaceutical company developing a proprietary drug candidate, linaprazan glurate (LG), a next generation and potential best-in-class Potassium Competitive Acid Blocker (PCAB), which is a fast-acting regulator of intragastric pH by a different MoA than PPI
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.